Skip To Main Content
Lilly
Menu closed
Lilly
  • Medical Home
    • Medical Information
Chat Click to chat
Question Submit a question

Information Request

Lilly Rep Request

Expand contact lilly
Lilly

You are now leaving the LillyMedical website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Eli Lilly and Company does not control, influence, or endorse this site, and the opinions, claims or comments expressed on this site should not be attributed to Eli Lilly and Company. Eli Lilly and Company is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit.

  1. Home Medical Right
  2. Medical Information Right
  3. Retsevmo ® ▼ (selpercatinib) Right
  4. Can Retsevmo® (selpercatinib) be given while receiving radiation?
Search selpercatinib information
Search Medical Information


Tips for searching:

• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences

Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.

Retsevmo ® ▼ (selpercatinib)

This information is intended for UK registered healthcare professionals only in response to your search for information. For current information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk

Back to search result(s)

Can Retsevmo® (selpercatinib) be given while receiving radiation?

Approximately 6% of the LIBRETTO-001 population received on-study radiation.

UK_cFAQ_SEL110_CONCURRENT_RADIATION
UK_cFAQ_SEL110_CONCURRENT_RADIATIONen-GB

Selpercatinib and Concurrent Radiation in LIBRETTO-001

Concurrent palliative radiotherapy was permitted In LIBRETTO-001 with sponsor approval and recommendation to hold selpercatinib for approximately 5 half-lives (approximately 2-3 days) before and after radiation therapy.1

Patients Who Received Selpercatinib and Concurrent Radiation in LIBRETTO-001

As of data cut-off date June 17, 2019, 27 patients received on-study palliative radiation, and 2 patients received curative radiation.2  Sites of radiation included

  • bone
  • brain
  • liver
  • lymph node
  • lung
  • neck, and
  • other (acetabulum, axilla, chest, hip, humerus, pancreatic node, pelvis, pleura, rib, sacrum, spine, and tonsil).2

Radiation Treatment-Emergent Adverse Events

Adverse events related to radiation included one grade 1 event of radiation neuropathy in the 20 mg twice daily cohort, and one grade 2 event of radiation necrosis in the 160 mg twice daily cohort.2 Neither event was considered to be related to selpercatinib.2

Upon review of the patients who received on-study radiation, 1 patient with non-small cell lung cancer (NSCLC) in the 160 mg twice daily cohort had symptoms considered to be possibly related to radiation.

The patient presented to a scheduled appointment 4 days after a second round of whole brain radiation. He was sent to the hospital with grade 3 muscular weakness, and grade 2 decreased appetite and malaise. The events were deemed likely due to numerous factors including

  • failure to thrive from underlying disease
  • whole brain radiation
  • hypotension and
  • thrush.2

None of the events were considered to be related to selpercatinib.2

LIBRETTO-001 Clinical Trial

LIBRETTO-001 is a multicenter, open-label, phase 1/2 study of selpercatinib administered orally to patients with rearranged (RET) fusion-positive solid tumors, RET-mutant medullary thyroid cancer, and other tumors with RET activation.1,3-5

LIBRETTO-001 Radiation Exclusion Criteria

Exclusion criteria included radiotherapy with a limited field of radiation for palliation within 1 week of the first dose of study treatment.

Exception to this criterion was patients receiving radiation to more than 30% of the bone marrow or with a wide field of radiation, which must be completed at least 4 weeks prior to the first dose of study treatment.1

References

1Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of selpercatinib in RET fusion–positive non–small-cell lung cancer. N Engl J Med. 2020;383(9):813-824. https://dx.doi.org/10.1056/NEJMoa2005653

2Data on file, Eli Lilly and Company and/or one of its subsidiaries.

3A study of selpercatinib (LOXO-292) in participants with advanced solid tumors, RET fusion-positive solid tumors, and medullary thyroid cancer (LIBRETTO-001). ClinicalTrials.gov identifier: NCT03157128. Updated March 4, 2024. Accessed March 5, 2024. https://www.clinicaltrials.gov/ct2/show/NCT03157128

4Wirth LJ, Sherman E, Robinson B, et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med. 2020;383(9):825-835. https://dx.doi.org/10.1056/NEJMoa2005651

5Retsevmo [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

Links to references and third-party websites are provided solely for your convenience and to facilitate easy access to the sources cited.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: 10 January 2023

Was this answer helpful?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms and conditions
  • Privacy Policy & Cookies
  • Accessibility Information
  • Cookie settings

    MI-LM-UK-1012 May-2025 | ® Registered Trademark of Eli Lilly and Company | © Eli Lilly and Company 2025.

    This site is published by Eli Lilly and Company Ltd and is intended for Healthcare Professionals in the United Kingdom

    Lilly